ACLX
Arcellx, Inc.
Key Financials
Revenue
$22.3M
↓ 79.4%
Operating Income
$-253083000
↓ 84.0%
Net Income
$-228934000
↓ 113.3%
EPS (Diluted)
$-4.07
↓ 103.5%
Total Liabilities
$201.6M
↓ 21.4%
Cash & Equivalents
$80.3M
↓ 24.1%
Total Assets
$604.0M
↓ 15.1%
Shareholders' Equity
$402.4M
↓ 11.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 4/17/2026 | View on SEC |
| SC 14D9/A | 4/17/2026 | View on SEC |
| SC TO-T/A | 4/17/2026 | View on SEC |
| SC 14D9/A | 4/1/2026 | View on SEC |
| SC TO-T/A | 4/1/2026 | View on SEC |
| SCHEDULE 13G/A | 3/26/2026 | View on SEC |
| 4 | 3/19/2026 | View on SEC |
| SC 14D9 | 3/6/2026 | View on SEC |
| SC TO-T | 3/6/2026 | View on SEC |
| SCHEDULE 13G/A | 3/6/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ACLX |
| Company Name | Arcellx, Inc. |
| CIK | 1786205 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 240-327-0603 |